Theriva Capex To Depreciation from 2010 to 2025

TOVX Stock  USD 1.19  0.04  3.48%   
Theriva Biologics Capex To Depreciation yearly trend continues to be fairly stable with very little volatility. Capex To Depreciation will likely drop to 0.01 in 2025. Capex To Depreciation is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. View All Fundamentals
 
Capex To Depreciation  
First Reported
2010-12-31
Previous Quarter
0.00729927
Current Value
0.006934
Quarterly Volatility
1.9711836
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 14.4 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.12. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Capex To Depreciation Growth Pattern

Below is the plot of the Capex To Depreciation of Theriva Biologics over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Theriva Biologics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Capex To Depreciation10 Years Trend
Very volatile
   Capex To Depreciation   
       Timeline  

Theriva Capex To Depreciation Regression Statistics

Arithmetic Mean1.04
Coefficient Of Variation190.31
Mean Deviation1.33
Median0.16
Standard Deviation1.97
Sample Variance3.89
Range8.5403
R-Value(0.07)
Mean Square Error4.14
R-Squared0.01
Significance0.79
Slope(0.03)
Total Sum of Squares58.28

Theriva Capex To Depreciation History

2025 0.006934
2024 0.007299
2023 1.5
2022 1.36
2019 0.0448
2018 0.0257
2017 0.87

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Capex To Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Depreciation 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.